Filter
258
Filtered Results: 258
Text search:
contraceptive
discontinuation
Featured
Recommendations
26
New Publications
85
Language
Document type
No document type
176
Studies & Reports
43
Guidelines
34
Manuals
2
Fact sheets
2
Infographics
1
Countries / Regions
India
37
Kenya
13
Rwanda
13
Zambia
10
Nepal
8
Senegal
8
Bangladesh
8
Ethiopia
8
Namibia
7
Sierra Leone
6
Malawi
6
Zimbabwe
6
Philippines
6
Ghana
5
Nigeria
5
Cambodia
5
Tanzania
5
South Africa
5
Liberia
5
Uganda
4
Haiti
3
Latin America and the Carribbean
3
Indonesia
3
Myanmar / Burma
3
Lesotho
2
Benin
2
Burkina Faso
2
Global
2
Jordan
2
Western and Central Europe
2
Egypt
2
Mali
2
Botswana
2
Somalia
2
Eswatini/ Swaziland
2
Tajikistan
1
Colombia
1
Albania
1
Peru
1
Dominican Republic
1
Congo, Democratic Republic of
1
South–East Asia Region
1
East and Southern Africa
1
Honduras
1
Authors & Publishers
Publication Years
Category
Countries
163
Clinical Guidelines
23
Women & Child Health
21
Capacity Building
14
Public Health
7
Key Resources
2
Pharmacy & Technologies
1
Toolboxes
HIV
32
TB
9
Mental Health
8
COVID-19
5
Pharmacy
5
NCDs
4
NTDs
3
Refugee
2
Conflict
2
Ebola
1
New England Journal of Medicine
April 9, 2021
DOI: 10.1056/NEJMoa2104840
The coronavirus disease 2019 (COVID-19) pandemic has created a global and gendered crisis that is compounding existing inequalities and disproportionately affecting girls and women. Emerging evidence from the COVID-19 crisis in 2020 shows school closures, disruptions in essential services and rising...
The revision of the SRHR Policy is based on the results of the analysis of the implementation process of the past policy, which has provided evidence to
ensure that the revised policy is relevant and effective. The revision has also been done with the participation of all national stakeholders who ...
Heart failure with a reduced ejection fraction (HFrEF) is a condition frequently encountered by healthcare professionals and, in order to achieve the best outcomes for patients, needs to be managed optimally. This guideline document is based on the European Society of Cardiology Guidelines for the t...
The document "Management of Type 2 Diabetes Mellitus" provides comprehensive guidelines for the diagnosis, prevention, and treatment of type 2 diabetes in adults. It emphasizes the importance of individualized glycemic targets, lifestyle interventions like diet and exercise, and the use of medicatio...
Selection and Use of Essential Medicines 2021
recommended
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo...
Module 3
Counsellors
July 2017
Module 3: Counsellors. This module is for staff who counsel people as they consider PrEP or start taking PrEP and support them in coping with side-effects and adherence strategies. Those who counsel PrEP users may be lay, peer or professional counsellors and hea...
These guidelines for the prevention and management of cardiovascular diseases are a critical ingredient for streamlining care across the entire health services provision continuum. They are a strategic component in achieving universal health coverage, securing affordable heal...
These guidelines provide updated evidence-based recommendations on the priority HCV-related topics from the 2018 WHO Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C infection and the 2017 WHO Guidelines on hepatitis B and C testing. These priority areas are:
...
The 7th edition of the Orange Guide provides practical guidance to health workers on the front line of TB control. It includes sections on HIV, MDR-TB and a review of the recommended treatment regimens
Prevention Of Cardiovascular Disease: Guidelines For Assessment And Management Or Cardiocascular Risk
recommended
This publication provides guidance on reducing disability and premature deaths from coronary heart disease, cerebrovascular disease and peripheral vascular disease in people at high risk, who have not yet experienced a cardiovascular event.
